表紙:医薬品ドラッグデリバリーの世界市場 - COVID-19の影響、2026年までの予測:投与経路別 (経口、注射型、埋め込み型、シロップ、ジェル、経肺、溶液、錠剤、シリンジ)、適応別 (がん、糖尿病) 、使用施設別 (病院)
市場調査レポート
商品コード
1037525

医薬品ドラッグデリバリーの世界市場 - COVID-19の影響、2026年までの予測:投与経路別 (経口、注射型、埋め込み型、シロップ、ジェル、経肺、溶液、錠剤、シリンジ)、適応別 (がん、糖尿病) 、使用施設別 (病院)

Pharmaceutical Drug Delivery Market by Route of Administration (Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes), Application (Cancer, Diabetes), Facility of Use (Hospitals), COVID-19 Impact - Global Forecast -2026

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 556 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
医薬品ドラッグデリバリーの世界市場 - COVID-19の影響、2026年までの予測:投与経路別 (経口、注射型、埋め込み型、シロップ、ジェル、経肺、溶液、錠剤、シリンジ)、適応別 (がん、糖尿病) 、使用施設別 (病院)
出版日: 2021年11月17日
発行: MarketsandMarkets
ページ情報: 英文 556 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の医薬品ドラッグデリバリーの市場規模は、2021年の1兆6,569億米ドルから、2026年までに2兆2,065億米ドルに達し、予測期間中のCAGRで5.9%の成長が予測されています。

医薬品ドラッグデリバリー市場の成長を促進する主な要因は、慢性疾患の有病率の急増、生物学的製剤市場の拡大、研究開発投資の増加、技術の進歩や新製品の発売などです。

当レポートでは、世界の医薬品ドラッグデリバリー市場について調査分析し、市場概要、業界動向、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
    • 市場課題
  • 医薬品ドラッグデリバリー市場に対するCOVID-19の影響
  • 業界動向
  • 規制分析
  • ポーターのファイブフォース分析
  • バリューチェーン分析
  • エコシステムマッピング
  • 顧客のビジネスに影響を与える動向/ディスラプション
  • 特許分析

第6章 医薬品ドラッグデリバリー市場:投与経路別

  • 経口ドラッグデリバリー
  • 注射型ドラッグデリバリーデリバリー
  • 局所ドラッグデリバリー
  • 眼用ドラッグデリバリー
  • 経肺ドラッグデリバリー
  • 経鼻ドラッグデリバリー
  • 経粘膜ドラッグデリバリー
  • 埋め込み型ドラッグデリバリー

第7章 医薬品ドラッグデリバリー市場:適応別

  • COVID-19の影響:適応別
  • 感染症
  • がん
  • 心血管疾患
  • 糖尿病
  • 呼吸器疾患
  • 中枢神経系障害
  • 自己免疫疾患
  • その他

第8章 医薬品ドラッグデリバリー市場:使用施設別

  • 病院
  • 外来手術センター/クリニック
  • 在宅医療
  • 診断センター
  • その他

第9章 医薬品ドラッグデリバリー市場:地域別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • スペイン
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 競合情勢

  • 概要
  • 主要企業戦略
  • 主要市場企業の収益シェア分析
  • 市場シェア分析
  • 競合ベンチマーキング
  • 競合リーダーシップマッピング
  • スタートアップの競合リーダーシップマッピング
  • 競合シナリオ

第11章 企業プロファイル

  • 主要企業
    • JOHNSON & JOHNSON
    • NOVARTIS INTERNATIONAL AG
    • F. HOFFMANN-LA ROCHE AG
    • PFIZER INC.
    • BECTON, DICKINSON AND COMPANY
    • GLAXOSMITHKLINE PLC
    • MERCK & CO., INC.
    • SANOFI
    • BAYER AG
    • 3M
    • ANTARES PHARMA, INC.
    • AMGEN, INC.
    • ABBVIE INC.
    • GENMAB A/S
    • GILEAD SCIENCES, INC.
    • BOEHRINGER INGELHEIM
    • ASTRAZENECA PLC
    • ELI LILLY AND COMPANY
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • BRISTOL-MYERS SQUIBB
  • その他の企業
    • GERRESHEIMER AG
    • BOSTON SCIENTIFIC CORPORATION
    • NIMBUS THERAPEUTICS
    • KITE PHARMA
    • IDEAYA BIOSCIENCES, INC.

第12章 付録

目次
Product Code: MD 3871

The global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period. Growth in the pharmaceutical drug delivery market can largely be attributed to factors such as the rising prevalence of chronic diseases, growing biologics market, increasing R&D investments, and technological advancements & new product launches.

On the other hand, the risk of needlestick injuries and the increased pricing pressure is expected to limit the market growth to some extent in the coming years.

The topical drug delivery segment is expected to grow at the highest CAGR during the forecast period

Based on route of administration, the pharmaceutical drug delivery market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery segment accounted for the highest CAGR of the pharmaceutical drug delivery market. This can be attributed to convenience and the ease of use, the ease of dosage, painless and non-invasive administration, and enhanced patient compliance.

The infectious diseases segment is expected to account for the largest share of the pharmaceutical drug delivery market

Based on application, the pharmaceutical drug delivery market is segmented into cancer, infectious diseases, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. In 2020, the infectious diseases segment accounted for the largest share of the pharmaceutical drug delivery market. The large share of this market segment can be attributed to the increasing prevalence of infectious diseases across the globe, increasing R&D expenditure for new drugs owing to the current COVID-19 pandemic scenario, and the rising number of FDA approvals for such drugs.

Asia Pacific is expected to account for the highest CAGR for players operating in the pharmaceutical drug delivery market

During the forecast period, the Asia Pacific is expected to be the fastest-growing regional market for pharmaceutical drug delivery. The rapid rise in the geriatric population, increased prevalence of chronic diseases, increased healthcare expenditure, increased R&D activities conducted in this region, growth in technological collaborations for pharmaceutical drug delivery technologies, favorable reimbursement policies, and growth in disposable incomes in the emerging Asian economies, such as China and India, are factors that are expected to drive the growth of the APAC market during the forecast period.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-35%, Tier 2-45%, and Tier 3-20%
  • By Designation - C-level-35%, Director-level-25%, Others-40%
  • By Region - North America-45%, Europe-30%, Asia-20%, Latin America- 3%, Middle East and Africa-2%

Key players in the Pharmaceutical Drug Delivery Market

Major players in this market include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).

Research Coverage:

The report analyzes the pharmaceutical drug delivery market and aims at estimating the market size and future growth potential of this market based on various segments such as route of administration, application, facility of use, and region. The report also includes a product portfolio matrix of various pharmaceutical drug delivery available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product & service offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global pharmaceutical drug delivery market. The report analyzes this market by route of administration, application, and facility of use
  • Solution Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global pharmaceutical drug delivery market
  • Market Development: Comprehensive information on the lucrative emerging markets by route of administration, applications, and facility of use
  • Market Diversification: Exhaustive information about new product enhancements, growing geographies, recent developments, and investments in the global pharmaceutical drug delivery market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global pharmaceutical drug delivery market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION AND SCOPE
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • 1.2.2 MARKETS COVERED
    • FIGURE 1 PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION
    • 1.2.3 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
    • TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
    • FIGURE 3 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
      • 2.1.2.3 Breakdown of primaries
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND PARTICIPANTS
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 7 PHARMACEUTICAL DRUG DELIVERY MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON
    • FIGURE 8 PHARMACEUTICAL SALES APPROACH
    • FIGURE 9 TOP-DOWN APPROACH
    • FIGURE 10 CAGR PROJECTIONS
    • FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE PHARMACEUTICAL DRUG DELIVERY MARKET (2021-2026): IMPACT ON MARKET GROWTH & CAGR
  • 2.3 DATA TRIANGULATION APPROACH
    • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 2 RISK ASSESSMENT: PHARMACEUTICAL DRUG DELIVERY MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 13 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD BILLION)
    • FIGURE 14 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION)
    • FIGURE 15 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2021 VS. 2026 (USD BILLION)
    • FIGURE 16 GEOGRAPHIC ANALYSIS: PHARMACEUTICAL DRUG DELIVERY MARKET

4 PREMIUM INSIGHTS

  • 4.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW
    • FIGURE 17 GROWING PREVALENCE OF CHRONIC DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE AND COUNTRY
    • FIGURE 18 THE HOSPITALS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET IN 2020
  • 4.3 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 CHINA TO REGISTER HIGHEST REVENUE GROWTH DURING FORECAST PERIOD
  • 4.4 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION (2019-2026)
    • FIGURE 20 NORTH AMERICA TO DOMINATE THE PHARMACEUTICAL DRUG DELIVERY MARKET DURING FORECAST PERIOD
  • 4.5 PHARMACEUTICAL DRUG DELIVERY MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 21 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • TABLE 3 PHARMACEUTICAL DRUG DELIVERY MARKET: IMPACT ANALYSIS
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Rising prevalence of chronic diseases
      • 5.2.1.2 Growth in the biologics market
    • TABLE 4 INDICATIVE LIST OF BIOLOGICS APPROVED BY THE FDA (2020)
      • 5.2.1.3 Technological advancements and new product launches
      • 5.2.1.4 Increasing investments in pharmaceutical R&D
    • FIGURE 22 NUMBER OF PHARMACEUTICAL COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010-2020)
    • FIGURE 23 GLOBAL PHARMA R&D SPENDING (2016-2020)
    • 5.2.2 MARKET RESTRAINTS
      • 5.2.2.1 Risk of needlestick injuries
    • 5.2.3 MARKET OPPORTUNITIES
      • 5.2.3.1 Self-administration and home care
      • 5.2.3.2 Rising demand for biosimilars and biologics
    • 5.2.4 MARKET CHALLENGES
      • 5.2.4.1 Pricing pressure
  • 5.3 COVID-19 IMPACT ON THE PHARMACEUTICAL DRUG DELIVERY MARKET
  • 5.4 INDUSTRY TRENDS
    • 5.4.1 INCREASING ADOPTION OF WEARABLE DRUG DELIVERY TECHNOLOGIES
    • 5.4.2 ADVANCEMENTS IN TECHNOLOGIES AND DESIGNS
  • 5.5 REGULATORY ANALYSIS
    • TABLE 5 REGULATORY SCENARIO BY COUNTRY
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 PORTER'S FIVE FORCES ANALYSIS (2020): PHARMACEUTICAL DRUG DELIVERY MARKET
    • 5.6.1 THREAT FROM NEW ENTRANTS
    • 5.6.2 THREAT FROM SUBSTITUTES
    • 5.6.3 BARGAINING POWER OF SUPPLIERS
    • 5.6.4 BARGAINING POWER OF BUYERS
    • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 VALUE CHAIN ANALYSIS
    • FIGURE 24 VALUE CHAIN ANALYSIS OF THE PHARMACEUTICAL DRUG DELIVERY MARKET
  • 5.8 ECOSYSTEM MAPPING
    • FIGURE 25 ECOSYSTEM OF THE PHARMACEUTICAL DRUG DELIVERY MARKET
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS
  • 5.10 PATENT ANALYSIS
    • 5.10.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
    • FIGURE 26 PATENT PUBLICATION, FILING, AND GRANT TRENDS (JANUARY 2011-OCTOBER 2021)
    • 5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 27 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011-OCTOBER 2021)
    • FIGURE 28 TOP APPLICANT COUNTRIES/REGIONS FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011-OCTOBER 2021)
    • TABLE 7 SOME PATENTS/ PATENT APPLICATIONS IN THE PHARMACEUTICAL DRUG DELIVERY MARKET, 2020-2021

6 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1 INTRODUCTION
    • TABLE 8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
  • 6.2 ORAL DRUG DELIVERY
    • TABLE 9 ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 10 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.2.1 SOLID ORAL DRUGS
    • TABLE 11 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 12 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.2.1.1 Tablets
        • 6.2.1.1.1 The development of mini-tablets is a key trend in this market segment
    • TABLE 13 TABLETS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.2.1.2 Capsules
        • 6.2.1.2.1 The easy absorption of drugs and decreased irritation in the GI tract drive the use of capsules
    • TABLE 14 CAPSULES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.2.1.3 Powders
        • 6.2.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms
    • TABLE 15 POWDERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.2.1.4 Pills
        • 6.2.1.4.1 The rising incidence of target ailments to propel the growth of the pills market
    • TABLE 16 PILLS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.2.2 LIQUID ORAL DRUGS
    • TABLE 17 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 18 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
      • 6.2.2.1 Syrups
        • 6.2.2.1.1 Syrups can be easily administered to patients with swallowing difficulties
    • TABLE 19 ORAL SYRUPS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.2.2.2 Solutions
        • 6.2.2.2.1 Solutions are generally preferred by geriatric and pediatric patients
    • TABLE 20 ORAL SOLUTIONS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.2.3 SEMI SOLID ORAL DRUGS
    • TABLE 21 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 22 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.2.3.1 Gels
        • 6.2.3.1.1 Gels are used for controlled drug release
    • TABLE 23 ORAL GELS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.2.3.2 Emulsions
        • 6.2.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis
    • TABLE 24 ORAL EMULSIONS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.2.3.3 Elixirs
        • 6.2.3.3.1 Elixirs are hydraulic in nature and contain sweet and flavored substances
    • TABLE 25 ORAL ELIXIRS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.3 INJECTABLE DRUG DELIVERY
    • TABLE 26 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 27 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.3.1 CONVENTIONAL INJECTION DEVICES
    • TABLE 28 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.3.1.1 By material
    • TABLE 29 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
        • 6.3.1.1.1 Glass Syringes
          • 6.3.1.1.1.1 Glass syringes are considered to be one of the most durable and safest materials to store biological drugs
    • TABLE 30 GLASS SYRINGES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
        • 6.3.1.1.2 Plastic Syringes
          • 6.3.1.1.2.1 Plastic syringes are reasonably priced as compared to their glass counterparts
    • TABLE 31 PLASTIC SYRINGES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.3.1.2 By product
    • TABLE 32 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
        • 6.3.1.2.1 Fillable syringes
          • 6.3.1.2.1.1 Ease of use and the variable dosing formulations of fillable syringes to drive the market growth
    • TABLE 33 FILLABLE SYRINGES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
        • 6.3.1.2.2 Prefilled syringes
          • 6.3.1.2.2.1 Prefilled syringes offer improved dose accuracy and increased patient convenience and safety
    • TABLE 34 PREFILLED SYRINGES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
      • 6.3.1.3 By usability
    • TABLE 35 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
        • 6.3.1.3.1 Reusable syringes
          • 6.3.1.3.1.1 Reusable syringes are easy to dismantle and clean
    • TABLE 36 REUSABLE SYRINGES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
        • 6.3.1.3.2 Disposable syringes
          • 6.3.1.3.2.1 Disposable syringes are widely used in medical practices due to their low cost and convenience
    • TABLE 37 DISPOSABLE SYRINGES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.3.2 SELF-INJECTION DEVICES
    • TABLE 38 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 39 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.3.2.1 Needle-free injectors
        • 6.3.2.1.1 Needle-free injectors enable faster drug delivery and show better reproducibility as compared to invasive drug delivery systems
    • TABLE 40 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.3.2.2 Autoinjectors
        • 6.3.2.2.1 Autoinjectors to provide improved patient satisfaction as compared to manual injections
    • TABLE 41 AUTOINJECTORS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.3.2.3 Pen injectors
        • 6.3.2.3.1 Pen injectors are generally used when medications have to be administered more than once a week
    • TABLE 42 COMMERCIALLY AVAILABLE KEY PEN INJECTORS
    • TABLE 43 PEN INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.3.2.4 Wearable injectors
        • 6.3.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare to support market growth
    • TABLE 44 WEARABLE INJECTORS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.3.3 OTHER INJECTOR DEVICES
    • TABLE 45 OTHER INJECTORS DEVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
  • 6.4 TOPICAL DRUG DELIVERY
    • TABLE 46 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 47 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.4.1 LIQUID FORMULATIONS
    • TABLE 48 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 49 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.4.1.1 Solutions
        • 6.4.1.1.1 Ease of use and ready availability of the dosage form to support market growth
    • TABLE 50 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.4.1.2 Suspensions
        • 6.4.1.2.1 Factors such as the high rate of bioavailability and the controlled onset of action to support the growth of the topical suspensions market
    • TABLE 51 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.4.2 SEMI SOLID FORMULATIONS
    • TABLE 52 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 53 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.4.2.1 Creams
        • 6.4.2.1.1 Creams are either water-in-oil or oil-in-water emulsions
    • TABLE 54 TOPICAL CREAMS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.4.2.2 Gels
        • 6.4.2.2.1 Faster drug release and greater patient acceptability to drive the market for topical gels
    • TABLE 55 TOPICAL GELS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.4.2.3 Ointments
        • 6.4.2.3.1 Ointments are widely used in analgesic indications
    • TABLE 56 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.4.2.4 Pastes
        • 6.4.2.4.1 Topical pastes are widely used for the treatment and prevention of skin irritation
    • TABLE 57 TOPICAL PASTES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.4.2.5 Lotions
        • 6.4.2.5.1 Easy administration of lotions to drive the demand among end users
    • TABLE 58 TOPICAL LOTIONS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.4.3 SOLID FORMULATIONS
    • TABLE 59 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 60 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.4.3.1 Suppositories
        • 6.4.3.1.1 Suppositories require a suitable base to ensure the compatibility and stability of the drug
    • TABLE 61 TOPICAL SUPPOSITORIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
      • 6.4.3.2 Powders
        • 6.4.3.2.1 Powders have a very fine particle size that covers a large surface area per unit weight
    • TABLE 62 TOPICAL POWDERS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.4.4 TRANSDERMAL PRODUCTS
    • TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 64 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.4.4.1 Transdermal patches
        • 6.4.4.1.1 Transdermal patches to prevent the premature metabolization of the drug through the liver
    • TABLE 65 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
      • 6.4.4.2 Transdermal gels
        • 6.4.4.2.1 Transdermal gels to help in a faster release of drugs on the target site
    • TABLE 66 TRANSDERMAL GELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.5 OCULAR DRUG DELIVERY
    • TABLE 67 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 68 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.5.1 LIQUID FORMULATIONS
    • TABLE 69 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 70 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.5.1.1 Eye drops
        • 6.5.1.1.1 Rising prevalence of cataracts and other eye diseases to drive the market growth
    • TABLE 71 COMMERCIALLY AVAILABLE EYE DROPS
    • TABLE 72 EYE DROPS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.5.1.2 Liquid sprays
        • 6.5.1.2.1 Liquid sprays to help in overcoming drawbacks associated with traditional eye drops
    • TABLE 73 LIQUID SPRAYS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.5.2 SEMI SOLID FORMULATIONS
    • TABLE 74 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 75 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.5.2.1 Gels
        • 6.5.2.1.1 The high viscosity of drugs, prolonged drug release, and the ease of drug administration are factors contributing to market growth
    • TABLE 76 OCULAR GELS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.5.2.2 Eye ointments
        • 6.5.2.2.1 Eye ointments are safe to use and help in improving ocular contact time with the drug
    • TABLE 77 EYE OINTMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.5.3 OCULAR DEVICES
    • TABLE 78 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 79 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.5.3.1 Drug-coated contact lenses
        • 6.5.3.1.1 Better eyesight offered by lenses and high compliance to drive the market for drug-coated contact lenses
    • TABLE 80 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
      • 6.5.3.2 Ocular inserts
        • 6.5.3.2.1 Ocular inserts to help in the sustained release of drugs in the eye
    • TABLE 81 OCULAR INSERTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.6 PULMONARY DRUG DELIVERY
    • TABLE 82 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 83 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.6.1 METERED-DOSE INHALERS
      • 6.6.1.1 Metered-dose inhalers overcome the problem of poor coordination between inhaler actuation and patient breath
    • TABLE 84 PULMONARY DRUG DELIVERY MARKET FOR METERED-DOSE INHALERS, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.6.2 DRY POWDER INHALERS
      • 6.6.2.1 Dry powder inhaler formulations are chemically more stable than their counterparts
    • TABLE 85 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.6.3 NEBULIZERS
    • TABLE 86 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 87 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.6.3.1 Jet nebulizers
        • 6.6.3.1.1 Jet nebulizers account for the largest share of the nebulizers market
    • TABLE 88 JET NEBULIZERS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
      • 6.6.3.2 Ultrasonic nebulizers
        • 6.6.3.2.1 Ultrasonic nebulizers are easy to use and comfortable to handle
    • TABLE 89 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
      • 6.6.3.3 Soft mist nebulizers
        • 6.6.3.3.1 Soft mist nebulizers are preferred for the treatment of severe COPD
    • TABLE 90 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.7 NASAL DRUG DELIVERY
    • TABLE 91 NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 92 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.7.1 NASAL DROPS
      • 6.7.1.1 Nasal drops are considered more efficient than nasal sprays
    • TABLE 93 NASAL DROPS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.7.2 NASAL SPRAYS
      • 6.7.2.1 Nasal sprays to help in relieving nasal congestion, runny nose, itchy nose, and sneezing
    • TABLE 94 NASAL SPRAYS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.7.3 NASAL POWDERS
      • 6.7.3.1 The absence of preservatives and superior stability of formulations are some of the advantages associated with nasal powders
    • TABLE 95 NASAL POWDERS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.7.4 NASAL GELS
      • 6.7.4.1 Nasal gels provide long-lasting relief from dry nasal passages and also reduce irritation caused by using soothing excipients
    • TABLE 96 NASAL GELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.8 TRANSMUCOSAL DRUG DELIVERY
    • TABLE 97 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 98 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.8.1 ORAL FORMULATIONS
    • TABLE 99 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 100 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.8.1.1 Buccal drug delivery
        • 6.8.1.1.1 Buccal drug delivery system is suitable for local and systematic therapies
    • TABLE 101 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.8.1.2 Sublingual drug delivery
        • 6.8.1.2.1 The rate of drug absorption through the sublingual route is 3-10 times higher than the oral route
    • TABLE 102 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES
    • TABLE 103 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 104 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
      • 6.8.2.1 Rectal transmucosal drug delivery
        • 6.8.2.1.1 The rectal route of drug delivery rapidly absorbs drugs that are aqueous in nature
    • TABLE 105 RECTAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
      • 6.8.2.2 Vaginal transmucosal drug delivery
        • 6.8.2.2.1 The permeability of the drug is high through the vaginal route of administration
    • TABLE 106 VAGINAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.9 IMPLANTABLE DRUG DELIVERY
    • TABLE 107 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 108 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • 6.9.1 ACTIVE IMPLANTABLE DRUG DELIVERY
      • 6.9.1.1 Active implantable devices are used for diagnostic monitoring, body fluids transportation, and ionizing radiation
    • TABLE 109 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.9.2 PASSIVE IMPLANTABLE DRUG DELIVERY
      • 6.9.2.1 Passive implants primarily include joint replacements, heart valves, aneurysm clips, coronary stents, and breast implants
    • TABLE 110 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)

7 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 COVID-19 IMPACT, BY APPLICATION
    • TABLE 111 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
  • 7.3 INFECTIOUS DISEASES
    • 7.3.1 HIGH BURDEN OF INFECTIOUS DISEASES ACROSS THE GLOBE TO DRIVE MARKET GROWTH
    • TABLE 112 PHARMACEUTICAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
  • 7.4 CANCER
    • 7.4.1 CANCER TO FORM A KEY THERAPEUTIC APPLICATION SEGMENT FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
    • FIGURE 29 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2020)
    • FIGURE 30 NUMBER OF ONCOLOGY CLINICAL TRIALS GLOBALLY FROM 2010 TO 2018 (IN THOUSANDS)
    • TABLE 113 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)
    • TABLE 114 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2019-2026 (USD BILLION)
  • 7.5 CARDIOVASCULAR DISEASES
    • 7.5.1 INCREASING PREVALENCE OF CVDS AND INCREASING INNOVATION IN THE PHARMACEUTICAL DRUG DELIVERY SEGMENT TO PROPEL MARKET GROWTH
    • TABLE 115 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)
    • TABLE 116 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
  • 7.6 DIABETES
    • 7.6.1 EMERGENCE OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH
    • FIGURE 31 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS)
    • TABLE 117 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY, 2019-2026 (USD BILLION)
  • 7.7 RESPIRATORY DISEASES
    • 7.7.1 HIGH PREVALENCE OF ASTHMA AND COPD TO DRIVE THE ADOPTION OF PHARMACEUTICAL DRUG DELIVERY
    • TABLE 118 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2020)
    • TABLE 119 PHARMACEUTICAL DRUG DELIVERY MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
  • 7.8 CENTRAL NERVOUS SYSTEM DISORDERS
    • 7.8.1 ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS ARE WIDELY USED IN THE TREATMENT OF CNS DISORDERS
    • TABLE 120 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019-2026 (USD BILLION)
  • 7.9 AUTOIMMUNE DISEASES
    • 7.9.1 AUTOIMMUNE DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
    • TABLE 121 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
  • 7.10 OTHER APPLICATIONS
    • 7.10.1 OPHTHALMIC DISORDERS
    • 7.10.2 ENDOCRINE DISORDERS
    • TABLE 122 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD BILLION)

8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE

  • 8.1 INTRODUCTION
    • TABLE 123 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
  • 8.2 HOSPITALS
    • 8.2.1 HOSPITALS DOMINATE THE GLOBAL MARKET WITH THE HIGH VOLUME OF PRESCRIPTIONS FOR INPATIENT AND OUTPATIENT VISITS
    • TABLE 124 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY, 2019-2026 (USD BILLION)
  • 8.3 AMBULATORY SURGERY CENTERS/CLINICS
    • 8.3.1 INCREASING PREFERENCE FOR AMBULATORY SURGERY CENTERS TO RESULT IN A SIGNIFICANT RISE IN DEMAND FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
    • TABLE 125 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019-2026 (USD BILLION)
  • 8.4 HOME CARE SETTINGS
    • 8.4.1 HOME CARE SETTINGS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
    • TABLE 126 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019-2026 (USD BILLION)
  • 8.5 DIAGNOSTIC CENTERS
    • 8.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
    • TABLE 127 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2019-2026 (USD BILLION)
  • 8.6 OTHER FACILITIES OF USE
    • TABLE 128 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES OF USE, BY COUNTRY, 2019-2026 (USD BILLION)

9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION

  • 9.1 INTRODUCTION
    • FIGURE 32 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT (2020)
    • TABLE 129 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2019-2026 (USD BILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 33 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT
    • TABLE 130 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • TABLE 131 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 132 NORTH AMERICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 133 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 134 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 135 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD MILLION)
    • TABLE 136 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 137 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 138 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 139 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 140 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 141 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 142 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 143 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 144 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 145 NORTH AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 146 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 147 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 148 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 149 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 150 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 151 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 152 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 153 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 154 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 155 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 156 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 157 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 158 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.2.1 US
      • 9.2.1.1 The US to dominate the North American pharmaceutical drug delivery market
    • TABLE 159 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 160 US: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 161 US: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 162 US: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 163 US: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD MILLION)
    • TABLE 165 US: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 166 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 167 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 168 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 169 US: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 170 US: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 171 US: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 172 US: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 173 US: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 174 US: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 175 US: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 176 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 177 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 178 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 179 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 180 US: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 181 US: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 182 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 183 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 184 US: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 185 US: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 186 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 187 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Government support for research and the prevalence of chronic diseases to drive the market in Canada
    • TABLE 188 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 189 CANADA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 190 CANADA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 191 CANADA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 192 CANADA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 193 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 194 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 195 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 196 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 197 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 198 CANADA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 199 CANADA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 200 CANADA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 201 CANADA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 202 CANADA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 203 CANADA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 204 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 205 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 206 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 207 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 208 CANADA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 209 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 210 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 211 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 212 CANADA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 213 CANADA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 214 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 215 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
  • 9.3 EUROPE
    • TABLE 216 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • TABLE 217 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 218 EUROPE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 219 EUROPE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 220 EUROPE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 221 EUROPE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 222 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 223 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 224 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 225 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 226 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 227 EUROPE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 228 EUROPE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 229 EUROPE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 230 EUROPE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 231 EUROPE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 232 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 233 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 234 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 235 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 236 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 237 EUROPE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 238 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 239 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 240 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 241 EUROPE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 242 EUROPE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 243 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 244 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Growing focus of pharmaceutical companies on the development of various drug delivery products to drive the market in Germany
    • TABLE 245 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 246 GERMANY: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 247 GERMANY: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 248 GERMANY: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 249 GERMANY: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 250 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 251 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 252 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 253 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 254 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 255 GERMANY: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 256 GERMANY: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 257 GERMANY: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 258 GERMANY: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 259 GERMANY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 260 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 261 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 262 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 263 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 264 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 265 GERMANY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 266 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 267 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 268 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 269 GERMANY: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 270 GERMANY: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 271 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 272 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.3.2 FRANCE
      • 9.3.2.1 Presence of leading pharmaceutical companies along with the increasing prevalence of chronic diseases to drive market growth in France
    • TABLE 273 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 274 FRANCE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 275 FRANCE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 276 FRANCE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 277 FRANCE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 278 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 279 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 280 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 281 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 282 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 283 FRANCE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 284 FRANCE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 285 FRANCE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 286 FRANCE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 287 FRANCE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 288 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 289 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 290 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 291 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 292 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 293 FRANCE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 294 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 295 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 296 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 297 FRANCE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 298 FRANCE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 299 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 300 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.3.3 ITALY
      • 9.3.3.1 Increasing focus on clinical research and the growing popularity of branded drugs to drive the demand for pharmaceutical drug manufacturing
    • TABLE 301 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 302 ITALY: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 303 ITALY: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 304 ITALY: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 305 ITALY: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 306 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 307 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 308 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 309 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 310 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 311 ITALY: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 312 ITALY: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 313 ITALY: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 314 ITALY: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 315 ITALY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 316 ITALY: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 317 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 318 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 319 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 320 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 321 ITALY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 322 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 323 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 324 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 325 ITALY: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 326 ITALY: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 327 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 328 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.3.4 UK
      • 9.3.4.1 Increasing incidence and prevalence of chronic and infectious diseases to drive the demand for pharmaceutical drug delivery in the UK
    • TABLE 329 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 330 UK: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 331 UK: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 332 UK: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 333 UK: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 334 UK: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 335 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 336 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 337 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 338 UK: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 339 UK: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 340 UK: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 341 UK: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 342 UK: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 343 UK: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 344 UK: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 345 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 346 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 347 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 348 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 349 UK: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 350 UK: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 351 UK: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 352 UK: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 353 UK: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 354 UK: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 355 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 356 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Increase in biologics production to support market growth
    • TABLE 357 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 358 SPAIN: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 359 SPAIN: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 360 SPAIN: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 361 SPAIN: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 362 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 363 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 364 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 365 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 366 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 367 SPAIN: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 368 SPAIN: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 369 SPAIN: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 370 SPAIN: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 371 SPAIN: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 372 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 373 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 374 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 375 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 376 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 377 SPAIN: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MLLION)
    • TABLE 378 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 379 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 380 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 381 SPAIN: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 382 SPAIN: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 383 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 384 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 385 ROE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 386 ROE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 387 ROE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 388 ROE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 389 ROE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 390 ROE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 391 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 392 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 393 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 394 ROE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 395 ROE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 396 ROE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 397 ROE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 398 ROE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 399 ROE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 400 ROE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 401 ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 402 ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 403 ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 404 ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 405 ROE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 406 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 407 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 408 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 409 ROE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 410 ROE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 411 ROE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 412 ROE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 34 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT
    • TABLE 413 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
    • TABLE 414 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 415 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 416 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 417 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 418 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 419 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 420 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 421 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 422 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 423 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 424 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 425 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 426 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 427 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 428 ASIA PACIFIC: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 429 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 430 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 431 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 432 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 433 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 434 ASIA PACIFIC: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 435 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 436 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 437 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 438 ASIA PACIFIC: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 439 ASIA PACIFIC: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 440 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 441 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 China had the largest diabetic population in the world in 2020
    • TABLE 442 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 443 CHINA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 444 CHINA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 445 CHINA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 446 CHINA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 447 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 448 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 449 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 450 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 451 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 452 CHINA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 453 CHINA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 454 CHINA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 455 CHINA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 456 CHINA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 457 CHINA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 458 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 459 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 460 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 461 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 462 CHINA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 463 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 464 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 465 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 466 CHINA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 467 CHINA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 468 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 469 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Favorable government initiatives and increased geriatric population to drive market growth in Japan
    • TABLE 470 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 471 JAPAN: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 472 JAPAN: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 473 JAPAN: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 474 JAPAN: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 475 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 476 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 477 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 478 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 479 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 480 JAPAN: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 481 JAPAN: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 482 JAPAN: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 483 JAPAN: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 484 JAPAN: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 485 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 486 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 487 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 488 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 489 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 490 JAPAN: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 491 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 492 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 493 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 494 JAPAN: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 495 JAPAN: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 496 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 497 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Growing generic demand and rising government initiatives to drive market growth in India
    • TABLE 498 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 499 INDIA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 500 INDIA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 501 INDIA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 502 INDIA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 503 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 504 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 505 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 506 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 507 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 508 INDIA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 509 INDIA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 510 INDIA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 511 INDIA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 512 INDIA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 513 INDIA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 514 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 515 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 516 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 517 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 518 INDIA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 519 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 520 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 521 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 522 INDIA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 523 INDIA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 524 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 525 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
    • 9.4.4 REST OF ASIA PACIFIC
    • TABLE 526 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 527 ROAPAC: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 528 ROAPAC: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 529 ROAPAC: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 530 ROAPAC: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 531 ROAPAC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 532 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 533 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 534 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 535 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 536 ROAPAC: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 537 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 538 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 539 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 540 ROAPAC: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 541 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 542 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 543 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 544 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 545 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 546 ROAPAC: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 547 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 548 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 549 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 550 ROAPAC: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 551 ROAPAC: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 552 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 553 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
  • 9.5 LATIN AMERICA
    • 9.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM
    • TABLE 554 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 555 LATIN AMERICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 556 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 557 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 558 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 559 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 560 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 561 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 562 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 563 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 564 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 565 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 566 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 567 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 568 LATIN AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 569 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 570 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 571 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 572 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 573 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 574 LATIN AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 575 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 576 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 577 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 578 LATIN AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 579 LATIN AMERICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 580 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 581 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 GOVERNMENT SUPPORT BOOSTING LOCAL PRODUCTION TO OFFER GROWTH OPPORTUNITIES FOR PHARMACEUTICAL MANUFACTURERS
    • TABLE 582 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2026 (USD BILLION)
    • TABLE 583 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 584 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 585 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 586 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019-2026 (USD MILLION)
    • TABLE 587 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 588 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019-2026 (USD BILLION)
    • TABLE 589 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019-2026 (USD BILLION)
    • TABLE 590 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019-2026 (USD BILLION)
    • TABLE 591 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 592 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 593 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 594 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 595 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 596 MIDDLE EAST & AFRICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019-2026 (USD MILLION)
    • TABLE 597 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 598 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 599 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 600 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019-2026 (USD BILLION)
    • TABLE 601 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 602 MIDDLE EAST & AFRICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 603 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 604 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 605 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 606 MIDDLE EAST & AFRICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 607 MIDDLE EAST & AFRICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019-2026 (USD BILLION)
    • TABLE 608 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
    • TABLE 609 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019-2026 (USD BILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE PHARMACEUTICAL DRUG DELIVERY MARKET
  • 10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
  • 10.4 MARKET SHARE ANALYSIS
    • FIGURE 36 PHARMACEUTICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2020
    • TABLE 610 PHARMACEUTICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION
  • 10.5 COMPETITIVE BENCHMARKING
    • TABLE 611 FOOTPRINT OF COMPANIES IN THE PHARMACEUTICAL DRUG DELIVERY MARKET
    • TABLE 612 COMPANY PRODUCT OFFERING FOOTPRINT (20 COMPANIES)
    • TABLE 613 COMPANY APPLICATION FOOTPRINT (20 COMPANIES)
    • TABLE 614 COMPANY FACILITY OF USE FOOTPRINT (20 COMPANIES)
    • TABLE 615 COMPANY REGION FOOTPRINT (20 COMPANIES)
  • 10.6 COMPETITIVE LEADERSHIP MAPPING
    • 10.6.1 STARS
    • 10.6.2 EMERGING LEADERS
    • 10.6.3 PERVASIVE PLAYERS
    • 10.6.4 PARTICIPANTS
    • FIGURE 37 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
  • 10.7 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS
    • 10.7.1 PROGRESSIVE COMPANIES
    • 10.7.2 DYNAMIC COMPANIES
    • 10.7.3 STARTING BLOCKS
    • 10.7.4 RESPONSIVE COMPANIES
    • FIGURE 38 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020)
  • 10.8 COMPETITIVE SCENARIO
    • 10.8.1 PRODUCT LAUNCHES & APPROVALS
    • 10.8.2 DEALS
    • 10.8.3 OTHER DEVELOPMENTS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
  • (Business Overview, Products, Key Insights, Recent Developments, MnM View)**
    • 11.1.1 JOHNSON & JOHNSON
    • TABLE 619 JOHNSON & JOHNSON: BUSINESS OVERVIEW
    • FIGURE 39 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020)
    • 11.1.2 NOVARTIS INTERNATIONAL AG
    • TABLE 620 NOVARTIS INTERNATIONAL AG: BUSINESS OVERVIEW
    • FIGURE 40 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2020)
    • 11.1.3 F. HOFFMANN-LA ROCHE AG
    • TABLE 621 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
    • FIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
    • 11.1.4 PFIZER INC.
    • TABLE 622 PFIZER INC. : BUSINESS OVERVIEW
    • FIGURE 42 PFIZER INC.: COMPANY SNAPSHOT (2020)
    • 11.1.5 BECTON, DICKINSON AND COMPANY
    • TABLE 623 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 43 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
    • 11.1.6 GLAXOSMITHKLINE PLC
    • TABLE 624 GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW
    • FIGURE 44 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2020)
    • 11.1.7 MERCK & CO., INC.
    • TABLE 625 MERCK & CO., INC.: BUSINESS OVERVIEW
    • FIGURE 45 MERCK & CO., INC.: COMPANY SNAPSHOT (2020)
    • 11.1.8 SANOFI
    • TABLE 626 SANOFI: BUSINESS OVERVIEW
    • FIGURE 46 SANOFI: COMPANY SNAPSHOT (2020)
    • 11.1.9 BAYER AG
    • TABLE 627 BAYER AG: BUSINESS OVERVIEW
    • FIGURE 47 BAYER AG: COMPANY SNAPSHOT (2020)
    • 11.1.10 3M
    • TABLE 628 3M: BUSINESS OVERVIEW
    • FIGURE 48 3M: COMPANY SNAPSHOT (2020)
    • 11.1.11 ANTARES PHARMA, INC.
    • TABLE 629 ANTARES PHARMA, INC.: BUSINESS OVERVIEW
    • 11.1.12 AMGEN, INC.
    • TABLE 630 AMGEN, INC. : BUSINESS OVERVIEW
    • FIGURE 49 AMGEN, INC. : COMPANY SNAPSHOT (2020)
    • 11.1.13 ABBVIE INC.
    • TABLE 631 ABBVIE INC.: BUSINESS OVERVIEW
    • 11.1.14 GENMAB A/S
    • TABLE 632 GENMAB A/S : BUSINESS OVERVIEW
    • 11.1.15 GILEAD SCIENCES, INC.
    • TABLE 633 GILEAD SCIENCES, INC.: BUSINESS OVERVIEW
    • 11.1.16 BOEHRINGER INGELHEIM
    • TABLE 634 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW
    • FIGURE 50 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2020)
    • 11.1.17 ASTRAZENECA PLC
    • TABLE 635 ASTRAZENECA PLC: BUSINESS OVERVIEW
    • FIGURE 51 ASTRAZENECA: COMPANY SNAPSHOT (2020)
    • 11.1.18 ELI LILLY AND COMPANY
    • TABLE 636 ELI LILLY AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020)
    • 11.1.19 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 637 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
    • 11.1.20 BRISTOL-MYERS SQUIBB
    • TABLE 638 BRISTOL-MYERS SQUIBB: BUSINESS OVERVIEW
  • *Details on Business Overview, Products, Key Insights, Recent Developments, MnM View might not be captured in case of unlisted companies.
  • 11.2 OTHER PLAYERS
    • 11.2.1 GERRESHEIMER AG
    • 11.2.2 BOSTON SCIENTIFIC CORPORATION
    • 11.2.3 NIMBUS THERAPEUTICS
    • 11.2.4 KITE PHARMA
    • 11.2.5 IDEAYA BIOSCIENCES, INC.

12 APPENDIX

  • 12.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 12.2 DISCUSSION GUIDE
  • 12.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.4 AVAILABLE CUSTOMIZATIONS
  • 12.5 RELATED REPORTS
  • 12.6 AUTHOR DETAILS